7 Stocks Under $10 Making Big Up Moves

As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Stocks that are in favor and making large moves is a segment of the market that I tweet about on a regular basis.These are also the exact type of stocks that I love to trade and alert to my subscribers in real-time.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

CPI Card Group

  • Tuesday's Range: $4.93-$5.24
  • 52-Week Range: $3.38-$13.50
  • Tuesday's Volume: 232,000
  • Three-Month Average Volume: 235,314

CPI Card Group  (PMTS)  engages in the design, production, data personalization, packaging and fulfillment of financial payment cards. This stock closed up 4% to $5.20 in Tuesday's trading session.

From a technical perspective, CPI Card Group spiked sharply higher on Tuesday right above its 50-day moving average of $4.75 a share with decent upside volume flows. This spike to the upside managed to push shares of CPI Card Group into breakout territory, after the stock closed above some previous resistance at $5.15 a share. Market players should now look for a continuation move to the upside in the short-term if this stock manages to take out Tuesday's intraday high of $5.24 a share with strong volume.

Traders should now look for long-biased trades in CPI Card Group as long as it's trending above Tuesday's intraday low of $4.91 a share or above its 20-day moving average of $4.71 a share and then once it sustains a move or close above Tuesday's intraday high of $5.24 a share with volume that registers near or above 235,314 shares. If that move gets underway soon, then this stock will set up to re-fill some of its previous gap-down-day zone from May that started at $8 a share.

Kura Oncology

  • Tuesday's Range: $5.05-$5.61
  • 52-Week Range: $2.50-$25.00
  • Tuesday's Volume: 190,000
  • Three-Month Average Volume: 309,285

Kura Oncology  (KURA) , a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. This stock closed up 8.2% to $5.50 in Tuesday's trading session.

From a technical perspective, Kura Oncology spiked sharply higher on Tuesday right off some near-term support at $5 a share with lighter-than-average volume. This rip to the upside managed to push shares of Kura Oncology into breakout territory, since the stock closed above some near-term overhead resistance at $5.45 a share. Market players should now look for a continuation move to the upside in the short-term if this stock manages to take out Tuesday's intraday high of $5.61 a share with strong volume.

Traders should now look for long-biased trades in Kura Oncology as long as it's trending above some key near-term support at $4.93 a share and then once it sustains a move or close above Tuesday's intraday high of $5.61 a share with volume that hits near or above 309,285 shares. If that move gets underway soon, then this stock will set up to re-test or possibly take out its next major overhead resistance at $6.89 a share.

Eclipse Resources

  • Tuesday's Range: $3.41-$3.61
  • 52-Week Range: $0.65-$4.42
  • Tuesday's Volume: 2.61 million
  • Three-Month Average Volume: 2.09 million

Eclipse Resources  (ECR) , an independent exploration and production company, acquires and develops oil and natural gas properties in the Appalachian Basin. This stock closed up 3.4% to $3.58 in Tuesday's trading session.

From a technical perspective, Eclipse Resources spiked notably higher on Tuesday right off its 20-day moving average of $3.36 a share with strong upside volume flows. This high-volume rip to the upside is now quickly pushing shares of Eclipse Resources within range of triggering a big breakout trade above some key overhead resistance levels. That trade will trigger if this stock manage to take out some near-term overhead resistance levels at $3.72 to $3.76 a share with high volume.

Traders should now look for long-biased trades in Eclipse Resources as long as it's trending above its 20-day moving average of $3.36 a share or above its 50-day moving average of $3.30 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 2.09 million shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $4.28 to its 52-week high of $4.42 a share.

Aegerion Pharmaceuticals

  • Tuesday's Range: $1.53-$1.71
  • 52-Week Range: $1.23-$18.29
  • Tuesday's Volume: 496,000
  • Three-Month Average Volume: 678,684

Aegerion Pharmaceuticals  (AEGR) , a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the U.S. This stock closed up 8.3% to $1.69 in Tuesday's trading session.

From a technical perspective, Aegerion Pharmaceuticals ripped sharply higher on Tuesday right off its 50-day moving average of $1.54 a share with decent upside volume flows. This high-volume rip to the upside managed to push this stock into breakout territory, since it closed above some near-term overhead resistance levels at $1.59 to $1.67 a share. This move is now quickly pushing shares of Aegerion Pharmaceuticals within range of triggering another big breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $1.71 to around $1.75 a share with high volume.

Traders should now look for long-biased trades in Aegerion Pharmaceuticals as long as it's trending above its 50-day moving average of $1.54 a share or above more near-term support at $1.50 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 678,684 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $2.12 to $2.32, or even $2.52 to $2.75 a share.

Curis

  • Tuesday's Range: $1.74-$1.82
  • 52-Week Range: $1.25-$3.18
  • Tuesday's Volume: 293,000
  • Three-Month Average Volume: 389,259

Curis  (CRIS) , a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. This stock closed up 2.8% to $1.79 in Tuesday's trading session.

From a technical perspective, Curis jumped notably higher on Tuesday right off its 20-day moving average of $1.74 a share with lighter-than-average volume. This stock recently formed a double bottom chart pattern, after shares found some buying interest at $1.65 to $1.68 a share. Following that potential bottom, shares of Curis have now started to trend higher back above both its 20-day and 50-day moving averages. That trend has now pushed this stock within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $1.82 to $1.83 a share with high volume.

Traders should now look for long-biased trades in Curis as long as it's trending above its 20-day moving average of $1.74 a share or above those recent double bottom support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 389,259 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $1.92 to $1.93, or even $2.05 to $2.17 a share.

Venaxis

  • Tuesday's Range: $3.10-$3.39
  • 52-Week Range: $1.60-$6.65
  • Tuesday's Volume: 123,000
  • Three-Month Average Volume: 29,231

Venaxis  (APPY)  develops its licensed animal health assets in the U.S. This stock closed up 9.3% to $3.39 in Tuesday's trading session.

From a technical perspective, Venaxis ripped notably higher on Tuesday right above some near-term support at $3.09 a share and back above both its 20-day moving average of $3.24 a share and its 50-day moving average of $3.38 a share with strong upside volume flows. This high-volume bump to the upside is now quickly pushing shares of Venaxis within range of triggering a major breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $3.40 to $3.70 a share and then above more key resistance levels at $3.90 to around $4 a share with high volume.

Traders should now look for long-biased trades in Venaxis as long as it's trending above some key near-term support levels at $3.09 to $2.99 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 29,231 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $4.75 to $6.65 a share.

Merrimack Pharmaceuticals

  • Tuesday's Range: $5.15-$5.27
  • 52-Week Range: $4.84-$11.00
  • Tuesday's Volume: 1.19 million
  • Three-Month Average Volume: 1.84 million

Merrimack Pharmaceuticals  (MACK) , a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the U.S. This stock closed up 2.5% to $5.27 in Tuesday's trading session.

From a technical perspective, Merrimack Pharmaceuticals jumped notably higher on Tuesday right above its new 52-week low of $4.84 a share with decent upside volume flows. This spike to the upside is now quickly pushing shares of Merrimack Pharmaceuticals within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $5.34 to its 20-day moving average of $5.37 a share with high volume.

Traders should now look for long-biased trades in Merrimack Pharmaceuticals as long as it's trending above Tuesday's intraday low of $5.15 a share or above its new 52-week low of $4.84 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.84 million shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $5.56 a share to its recent gap-down-day high of around $5.75 a share. Any high-volume move above $5.75 will then give this stock a chance to re-fill some of its previous gap-down-day zone from earlier this month that started at $6.12 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.

More from Stocks

Lee Munson on the Market, Trade and the Possibility of a Recession

Lee Munson on the Market, Trade and the Possibility of a Recession

Buy These 3 Killer Tech Stocks, Says Wall Street's #1 Analyst

Buy These 3 Killer Tech Stocks, Says Wall Street's #1 Analyst

How Tariffs Can Impact the U.S. and the Global Capital Markets

How Tariffs Can Impact the U.S. and the Global Capital Markets

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Trump's Attack on the Federal Reserve and China Leaves Investors Feeling Strange

Trump's Attack on the Federal Reserve and China Leaves Investors Feeling Strange